<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113745</url>
  </required_header>
  <id_info>
    <org_study_id>AXS-12-302</org_study_id>
    <nct_id>NCT05113745</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy</brief_title>
  <official_title>A Study to Assess the Long-term Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axsome Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axsome Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the long-term efficacy and safety of AXS-12 in narcoleptic subjects&#xD;
      with cataplexy and excessive daytime sleepiness (EDS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center trial consisting of a 24-week open-label period, followed by a&#xD;
      4-week double-blind, placebo-controlled, randomized withdrawal period. At the Week 24 visit,&#xD;
      subjects will be randomized in a 1:1 ratio either to continue to receive AXS-12 or to switch&#xD;
      to placebo, for the next 4 weeks. Eligible subjects will have previously participated in the&#xD;
      AXS-12-301 study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 20, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label treatment period, followed by a double-blind treatment period.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term safety as measured by the incidence of treatment-emergent adverse events</measure>
    <time_frame>Up to 28 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy as measured by change in frequency of cataplexy attacks from baseline.</measure>
    <time_frame>Baseline to Week 27</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Narcolepsy</condition>
  <condition>Cataplexy</condition>
  <condition>Excessive Daytime Sleepiness</condition>
  <arm_group>
    <arm_group_label>AXS-12 (reboxetine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 24 weeks in open-label period&#xD;
Up to 4 weeks in randomized double-blind period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Up to 4 weeks in randomized double-blind period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXS-12 (reboxetine)</intervention_name>
    <description>AXS-12 tablets, taken twice daily</description>
    <arm_group_label>AXS-12 (reboxetine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets, taken twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Completed the treatment period of Study AXS-12-301&#xD;
&#xD;
          -  Willing and able to comply with the study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant change in medical history or concomitant medications since enrolling in&#xD;
             the AXS-12-301 study which, in the opinion of the Investigator, would render the&#xD;
             subject unsuitable to receive AXS-12&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Denver</city>
        <state>North Carolina</state>
        <zip>28037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.axsome.com</url>
    <description>Axsome Therapeutics Website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AXS-12</keyword>
  <keyword>Narcolepsy</keyword>
  <keyword>Cataplexy</keyword>
  <keyword>Excessive Daytime Sleepiness</keyword>
  <keyword>Reboxetine</keyword>
  <keyword>Axsome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
    <mesh_term>Cataplexy</mesh_term>
    <mesh_term>Sleepiness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reboxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

